Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $14
CorMedix (CRMD) Q3 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript
CorMedix: Q3 Earnings Snapshot
Cormedix Q3 2026 Earnings Call Transcript
Cormedix Q3 EPS $(0.19) Misses $(0.10) Estimate, Sales $54.519M Beat $53.227M Estimate
Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $337.061M Est
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15
Needham Maintains Buy on Cormedix, Raises Price Target to $14
CorMedix stock gains as Heron deal adds four products
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
Needham Maintains Buy on Cormedix, Lowers Price Target to $12
CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position
CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
CorMedix Reaffirms FY26 Total Sales Guidance Of $325M-$345M; Anticipates That The DefenCath Add-On Will Decline Sequentially In Q2 2027, With A QoQ Increase In Q3 And/Or Q4
CRMD Stock Hits Fresh 52-Week Low On DaVita’s Warning Of Sharp 2027 DefenCath Reimbursement Drop
Needham Reiterates Buy on Cormedix, Maintains $15 Price Target
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.